Angiotensin II protects against α-synuclein toxicity and reduces protein aggregation in vitro

Biochemical and Biophysical Research Communications

Volumn 363, Issue 3, 2007, Pages 846-851

  Grammatopoulos, Tom N ^a   Outeiro, Tiago F ^a,b   Hyman, Bradley T ^a   Standaert, David G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Angiotensin; AT receptor; Inclusion; Losartan; Parkinson's disease; PD123319; Renin angiotensin system; Synphilin 1; Synuclein

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALPHA SYNUCLEIN; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; LOSARTAN; PROTEIN;

ARTICLE; CELL INCLUSION; CONTROLLED STUDY; DRUG MECHANISM; GLIOMA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL SIGNIFICANCE;

ALPHA-SYNUCLEIN; ANGIOTENSIN II; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; INCLUSION BODIES; LOSARTAN; PARKINSON DISEASE; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; VASOCONSTRICTOR AGENTS;

EID: 34848821185     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.09.043     Document Type: Article

References (47)

1. Gwinn-Hardy K. Genetics of Parkinsonism. Mov. Disord. 17 (2002) 645-656
2. Foltynie T., Sawcer S., Brayne C., and Barker R.A. The genetic basis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 73 (2002) 363-370
3. Polymeropoulos M.H., Levedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Pappetropoulso T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di lorio G., Golbe L.I., and Nussbaum R.L. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
4. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
5. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., and Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 239 (1997) 45-48
6. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L., and Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol. 152 (1998) 367-372
7. Wolozin B., and Behl C. Mechanisms of neurodegenerative disorders: Part 1: protein aggregates. Arch. Neurol. 57 (2000) 793-796
8. Phillips M.I. Functions of angiotensin in the central nervous system. Annu. Rev. Physiol. 49 (1987) 413-435
9. Wright J.W., and Harding J.W. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci. Biobehav. Rev. 18 (1994) 21-53
10. Gasparo M.D., Catt K.J., Inagami T., Wright J.W., and Unger T.H. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol. Rev. 52 (2000) 415-472
11. Lippoldt A., Paul M., Fuxe K., and Ganten D. The brain renin-angiotensin system: molecular mechanisms of cell to cell interactions. Clin. Exp. Hypertens. 17 (1995) 251-266
12. Phillips M.I., Speakman E.A., and Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul. Pept. 22 (1993) 1-20
13. Thone-Reineke C., Zimmermann M., Neumann C., Krikov M., Li J., Gerova N., and Unger T. Are Angiotensin receptor blockers neuroprotective?. Curr. Hypertens. Rep. 6 (2004) 257-266
14. Wakutani Y., Kowa H., Kusumi M., Yamagata K., Wada-Isoe K., Adachi Y., Takeshima T., Urakami K., and Nakashima K. Genetic analysis of vascular factors in Alzheimer's disease. Ann. N. Y. Acad. Sci. 977 (2002) 232-238
15. Wright J.W., and Harding J.W. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci. Biobehav. Rev. 18 (1994) 21-53
16. Ge J., and Barnes N.M. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur. J. Pharmacol. 297 (1996) 299-306
17. Lin J.J., Yueh K.C., Chang D.C., and Lin S.Z. Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson's disease. J. Neurol. Sci. 199 (2002) 25-29
18. Armando I., Jezova M., Bregonzio C., Baiardi G., and Saavedra J.M. Angiotensin II AT1 and AT2 receptor types regulate basal and stress-induced adrenomedullary catecholamine production through transcriptional regulation of tyrosine hydroxylase. Ann. N. Y. Acad. Sci. 1018 (2004) 302-309
19. Glass M.J., Huang J., Speth R.C., Iadecola C., and Pickel V.M. Angiotensin II AT-1A receptor immunolabeling in rat medial nucleus tractus solitarius neurons: subcellular targeting and relationships with catecholamines. Neuroscience 130 (2005) 713-723
20. Ma F.Y., Grattan D.R., Bobrovskaya L., Dunkley P.R., and Bunn S.J. Angiotensin II regulates tyrosine hydroxylase activity and mRNA expression in rat mediobasal hypothalamic cultures: the role of specific protein kinases. J. Neurochem. 90 (2004) 431-441
21. Ogier M., Bezin L., Cottet-Emard J.M., Bader M., Vincent M., Pequignot J.M., McGregor J., and Bricca G. Delayed maturation of catecholamine phenotype in nucleus tractus solitarius of rats with glial angiotensinogen depletion. Hypertension 42 (2003) 978-984
22. Lu D., Yang H., Shaw G., and Raizada M.K. Angiotensin II-induced nuclear targeting of the angiotensin type 1 (AT1) receptor in brain neurons. Endocrinology 139 (1998) 365-375
23. Grammatopoulos T., Morris K., Ferguson P., and Weyhenmeyer J. Angiotensin protects cortical neurons from hypoxic-induced apoptosis via the angiotensin type 2 receptor. Brain Res. Mol. Brain Res. 99 (2002) 114-124
24. Grammatopoulos T.N., Ahmadi F., Jones S.M., Rariss M.W., Weyhenmeyer J.A., and Zawada W.M. Angiotensin II protects cultures midbrain dopaminergic neurons against rotenone-induced cell death. Brain Res. 1045 (2005) 64-71
25. Grammatopoulos T.N., Jones S.M., Ahmadi F.A., Hoover B.R., Snell L.D., Skoch J., Jhaveri V.V., Poczobutt A.M., Weyhenmeyer J.A., and Zawada W.M. Angiotensin type 1 receptor antagonist losartan reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2 (2007) 1
26. Jenkins T.A., Wong J.Y., Howells D.W., Mendelsohn F.A., and Chai S.Y. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J. Neurochem. 73 (1999) 214-219
27. Kurosaki R., Muramatsu Y., Kato H., Watanabe Y., Imai Y., Itoyama Y., and Araki T. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. Eur. Neuropsychopharmacol. 15 (2005) 57-67
28. Lopez-Real A., Rey P., Soto-Otero R., Mendez-Alvarez E., and Labandeira-Garcia J.L. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J. Neurosci. Res. 81 (2005) 865-873
29. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., and Akram M. The Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76 (2001) 1265-1274
30. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
31. Lansbury Jr. P.T., and Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Genet. Dev. 12 (2002) 299-306
32. Rochet J.C., Outeiro T.F., Conway K.A., Ding T.T., Volles M.J., Lashuel H.A., Bieganski R.M., Lindquist S.L., and Lansbury P.T. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23 (2004) 23-34
33. Hashimoto M., Rockenstein E., and Masliah E. Transgenic models of alpha-synuclein pathology: past present and future. Ann. N. Y. Acad. Sci. 991 (2003) 171-188
34. McLean P.J., Kawamata H., Ribich S., and Hyman B.T. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275 (2000) 8812-8816
35. McLean P.J., Kawamata H., and Hyman B.T. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 104 (2001) 901-912
36. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., Volk C.B., Maxwell M.M., Rochet J.C., McLean P.J., Young A.B., Abagyan R., Feany M.B., Hyman B.T., and Kazantsev A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317 (2007) 516-519
37. Sardinia M.F., Hanesworth J.M., Krishan F., and Harding L.W. AT4 receptor binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 15 (1994) 1399-1406
38. Groth W., Blume A., Gohlke P., Unger T., and Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J. Hypertens. 21 (2003) 2175-2182
39. Lou M., Blume A., Zhao Y., Gohlke P., Deuschl G., Herdegen T., and Culman J. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury apoptosis and inflammatory responses in the rat. J. Cereb. Blood Flow Metab. 24 (2004) 536-547
40. Hemming M.L., and Selkoe D.J. Amyloid beta-protein is degraded by cellular angiotensinconvertingenzyme (ACE) and elevated by an ACE inhibitor. J. Biol. Chem. 280 (2005) 37644-37650
41. Hemming M.L., Selkoe D.J., and Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis. 26 (2007) 273-281
42. Chai S.Y., Fernando R., Peck G., Ye S.Y., Mendelsohn F.A., Jenkins T.A., and Albiston A.L. The angiotensin IV/AT4 receptor. Cell. Mol. Life Sci. 61 (2004) 2728-2737
43. Pederson E.S., Krishnan R., Harding J.W., and Wright J.W. A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul. Pept. 102 (2001) 147-156
44. Wright J.W., Stubley L., Pederson E.S., Kramar E.A., Hanesworth J.M., and Harding J.W. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J. Neurosci. 19 (1999) 3952-3961
45. Grammatopoulos T.N., Johnson V., Moore S.A., Andres R., and Weyhenmeyer J.A. Angiotensin type 2 receptor neuroprotection against chemical hypoxia is dependent on the delayed rectifier K+ channel, Na+/Ca2+ exchanger and Na+/K+ ATPase in primary cortical cultures. Neurosci. Res. 50 (2004) 299-306
46. Grammatopoulos T.N., Morris K., Bachar C., Moore S., Andres R., and Weyhenmeyer J.A. Angiotensin II attenuates chemical hypoxia-induced caspase-3 activation in primary cortical neuronal cultures. Brain Res. Bull. 62 (2004) 297-303
47. Rey P., Lopez-Real A., Sanchez-Iglesias S., Munoz A., Soto-Otero R., and Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 28 (2007) 555-567